Phil: Harrow Partners With Healthcare Market Access Technology Platforms to Expand U.S. Availability of Vevye

NASHVILLE, Tenn.-Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced that it has partnered with three leading healthcare technology platforms to expand U.S. availability of Vevye (cyclosporine ophthalmic solution) 0.1%, a patented, nonpreserved, twice-daily (BID) dosed, ophthalmic solution prescription drug based on a "water-free" semifluorinated alkane (SFA) eye drop technology. Vevye, uniquely dispensed in a 10 microliter drop, is the first and only cyclosporine-based product indicated for treating both signs and symptoms of dry eye disease (DED).